Parakrama Tissa Chandrasoma

20080014283, Jan 17, 2008

Aug 23, 2007

11/844218

Parakrama Chandrasoma - Pasadena CA, US

A61K 33/00
A61P 1/00
C12Q 1/02

424600000, 435029000

Medications for the prevention and treatment of the progression of gastroesophageal reflux disease to adenocarcinoma, and more specifically to medications that operate in accordance with a new mechanistic understanding of the sequence of changes whereby gastroesophageal reflux disease progresses to adenocarcinoma are provided. The medications for the prevention and treatment of reflux-induced adenocarcinoma are based on (1) recognizing cardiac mucosa as an abnormal epithelium that should be a target of treatment, (2) preventing cardiac mucosa from progressing to intestinal metaplasia (Barrett esophagus), and (3) promoting the conversion of cardiac mucosa to oxyntocardiac mucosa, which is recognized by the invention as being a benign epithelium that does not progress to intestinal metaplasia (Barrett esophagus) and adenocarcinoma. In patients who already have intestinal metaplasia at the time of detection, the medications for prevention and treatment require a preliminary step whereby the intestinal metaplasia is reverted to cardiac mucosa before it can be induced to convert to the benign oxyntocardiac mucosa.

20070178510, Aug 2, 2007

Jan 30, 2007

11/669059

Parakrama Chandrasoma - Pasadena CA, US

C12Q 1/68
G01N 33/48

435006000, 435040500

A novel methodology for diagnosing and treating gastroesophageal reflux disease is provided. These methodologies are based on the discovery of a new disease mechanism called hereinafter “reflux carditis”, which is a novel mechanistic view of reflux disease that recognizes cardiac mucosa, which has heretofore been regarded as a normal epithelium in the stomach and an abnormal epithelium in the esophagus, as an abnormal mucosa in both the esophagus and stomach.

20210321940, Oct 21, 2021

Jan 26, 2021

17/158783

Parakrama Chandrasoma - Pasadena CA, US

A61B 5/00
A61B 5/107
A61B 1/273
A61B 10/04
G16H 50/50
G16H 50/30
G16H 10/60

Determining the progression of reflux disease in the esophagus of a patient includes identifying the location of an endoscopic gastroesophageal junction in the esophagus, removing a length of tissue of the esophagus that includes a portion of the endoscopic gastroesophageal junction, and identifying the proximal limit of tissue containing cardiac epithelium. Determining the length of the squamo-oxyntic gap of the biopsied tissue can involve measuring the length of tissue extending between the proximal limit of tissue containing gastric oxyntic epithelium to the proximal limit of tissue containing cardiac epithelium. A linear relationship can be determined from a slope of a line extending between a first data point and a second data point that can determine a target age of the patient when the lower esophageal sphincter will have a certain length.

20170290542, Oct 12, 2017

Apr 6, 2017

15/481225

PARAKRAMA CHANDRASOMA - Pasadena CA, US

A61B 5/00
A61B 10/02
A61B 1/233
A61B 10/04

Determining the progression of reflux disease in the esophagus of a patient includes identifying the location of an endoscopic gastroesophageal junction in the esophagus, removing a length of tissue of the esophagus that includes a portion of the endoscopic gastroesophageal junction, and identifying the proximal limit of tissue containing cardiac epithelium. Determining the length of the squamo-oxyntic gap of the biopsied tissue can involve measuring the length of tissue extending between the proximal limit of tissue containing gastric oxyntic epithelium to the proximal limit of tissue containing cardiac epithelium. A linear relationship can be determined from a slope of a line extending between a first data point and a second data point that can determine a target age of the patient when the lower esophageal sphincter will have a certain length.